DYNACURE S.A. has a market cap of $314.9 million.
J.P. Morgan, BofA Securities and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Co. was co-manager.
DYNACURE S.A. provided the following description of their company for its IPO: “We are a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. We are initially focused on developing treatments for neuromuscular diseases, beginning with myotubular and centronuclear myopathies, or CNM, a group of devastating rare genetic disorders characterized by severe muscle weakness, or myopathy, with shortened life expectancy and significant morbidity. Our lead product candidate, DYN101, is an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of CNM patients across multiple mutations in both adult and pediatric populations. ASOs are single-stranded, chemically synthesized nucleic acid analogs designed to bind a corresponding strand of ribonucleic acid and alter protein expression. We are conducting a Phase 1/2 clinical trial in Europe of DYN101, which is called UNITE-CNM, and we intend to expand this trial to sites in the United States in the second half of 2021. We expect to report interim pharmacokinetic, or PK, and safety data from this trial in the second half of 2022 and expect to report final data in 2023. DYN101 has been granted orphan drug designation by the U.S. Food and Drug Administration, or FDA, and European Medicines Agency, or EMA, and rare pediatric disease designation by the FDA. In addition, we are currently preparing to conduct a Phase 1/2 clinical trial of DYN101 called DyNaMic in a pediatric population in Europe, which may be expanded to the United States. Following interim data from the UNITE-CNM Phase 1/2 trial in adults, and subject to regulatory authorization, we expect to commence this pediatric clinical trial in the second half of 2022 in Europe. Our second program, DYN201, is a discovery-stage program focused on developing a treatment for a group of rare inherited neurodegenerative disorders characterized by spasticity and motor dysfunction called hereditary spastic paraplegias, or HSP. *Note: Net loss figures is in U.S. dollars, converted from euros in the prospectus, for the 12 months that ended March 31, 2021. “.
DYNACURE S.A. was founded in 2016 and has 25 employees. The company is located at Bioparc III 850, Boulevard Sébastien Brant 67400 Illkirch-Graffenstaden France and can be reached via phone at +33 3 74 95 20 50 or on the web at http://www.dynacure.com/.
Receive News & Ratings for DYNACURE S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DYNACURE S.A. and related companies with MarketBeat.com's FREE daily email newsletter.